MOJ ISSN: 2381-179X MOJCR

Clinical & Medical Case Reports
Case Report
Volume 5 Issue 1 - 2016
Intraarticular Administration of Dobesilate for the Treatment of Knee Rheumatoid Arthritis
Pedro Cuevas1,2*, Tomás Fernández-Jaén2,3, Pedro Guillen2,3, Javier Angulo4 and Guillermo Giménez-Gallego2,5
1Facultad de Medicina, Universidad Alfonso X, Spain
2Fundacion Pedro Guillén, Clínica CEMTRO, Spain
3Facultad de Medicina, Universidad Católica San Antonio, Spain
4Departamento de Investigación, Hospital Universitario Ramón y Cajal, Spain
5Departamento de Estructura y Función de Proteínas, Centro de Investigaciones Biológicas, Spain
Received: April 05, 2016 | Published: November 04, 2016
*Corresponding author: Pedro Cuevas, Facultad de Medicina, Universidad Alfonso X, Spain, Email:
Citation: Cuevas P, Fernández-Jaén T, Guillen P, Angulo J, Giménez-Gallego G (2016) Intraarticular Administration of Dobesilate for the Treatment of Knee Rheumatoid Arthritis. MOJ Clin Med Case Rep 5(1): 00119. DOI: 10.15406/mojcr.2016.05.00119

Summary

Rheumatoid arthritis is an inflammatory condition that causes a negative effect in patient well-being. Fibroblast growth factor participates in the pathology of rheumatoid arthritis through its proliferative, inflammatory and angiogenic activities. Dobesilate, an inhibitor of fibroblast growth factor shows marked anti-proliferative, anti-inflammatory, and anti-angiogenic activities. Our study shows that intraarticular application of dobesilate is effective in reducing symptoms and signs in patients with chronic knee rheumatoid arthritis.

Keywords: Rheumatoid arthritis; Dobesilate; Etamsylate; Intraarticular application; Fibroblast growth factor

Introduction

Inflammation contributes to the pathogenesis of rheumatoid osteoarthritis through formation of various catabolic and pro-inflammatory mediators which alter the balance of cartilage matrix degradation and repair [1]. In this condition, disturbed synovial and granulation tissue (so-called pannus formation) erodes and destroys the articular surface, and also invades subchondral bone tissue in part through osteoclast-like giant cells activity. Treatment of arthritis aims to control pain and maintain or improve physical function and quality of life. Currently, guidelines for the treatment of refractory knee rheumatoid arthritis recommended the use of intraarticular glucocorticoids. However, there is a big amount of data showing that this treatment frequently produces insufficient benefit with the associated risk of undesirable side effects [2]. Drugs that inhibit joint destruction are known as disease-modifying antirheumatic drugs (DMARDs) such as sulfasalazine, antimalarials, penicillamine, gold, methotrexate, azathioprine, leflunomide and cyclophosphamide [3]. These drugs are not always effective and frequently may lose effectiveness with time or may cause adverse effects. Therefore alternative DMARDs are needed and one class of new biologics agents have been developed as tumor necrosis factor alpha (TNF-α) inhibitors (adalimumab, etanercept, infiximab). However, a high risk of serious infection could be associated with anti-TNF-α therapy [4]. Furthermore, the cost of anti-TNF-α therapy could limit its use. For all these reasons, novel but safe and efficient new therapy seems desirable for treating rheumatoid arthritis and its sequelae. Since clinical and animal data have been supporting a key role of fibroblast growth factor (FGF) in arthritis pathophysiology [5-11], its inhibition may be an attractive mean for arthritis treatment. In this context, we evaluated the local administration of dobesilate in solution, an inhibitor of fibroblast growth factor (FGF) activities, whose anti-inflammatory and anti-angiogenesis activities have been shown recently in several diseases and animal models [12-15]. Dobesilate is a synthetic vasoactive drug that has been used orally as vasculotropic, for many years with a good safety profile [16]. However oral administration is not the best choice for dobesilate to reach the adequate concentration at the joint cavity. Dobesilate has a very low solubility at the acidic pH of the stomach, and further, readily oxidises at the duodenal pH. Accordingly, a local delivery seems a better choice in order to reach appropriate therapeutic concentrations of dobesilate in the case of well-delimited targets, as is the case of knee rheumatoid arthritis. We report here that local intraarticular application of dobesilate solution improved symptoms and signs in knee rheumatoid arthritis.

Patients and Treatment

Five patients with chronic knee rheumatoid arthritic joint participated in this study. After approval of our ethical committee, patients signed an informed consent form, which includes a comprehensive description of the proposed procedure with dobesilate. Clinical assessment of rheumatoid arthritis was evaluated at baseline, seven days and two months after dobesilate injection according to the concepts of the World Health Organization’s International Classification of Functioning Disability and Health (Geneva 2001). Temperature, hyperaemia, effusion/swelling and pain were evaluated. Temperature was measured using a contactless infrared thermometer. Clinical signs were graded using the following scale: 0: no signs of involvement; 1: moderate, 2: high and 3: severe. Intraarticular dobesilate injection was administered into a single knee as a 12.5% solution (2ml) of diethylamonium2, 5-dihidroxy benzenesulfonate (etamsylate, Dicynone®, Sanofi-Aventis. Paris, France). Mean clinical scores before and after one week of treatment with dobesilate were compared by paired t-test. A p<0.05 was considered significant.

Results and Discussion

After one week of treatment all clinical scores were significantly reduced (Figure 1) and the clinical improvement was maintained after two months follow-up. Patients did not show any apparent side-effect that may be attributed to the treatment. Rheumatoid arthritis is an inflammation-dependent disease. The hallmark of this condition is the progressive destruction of articular joints characterized by invasive synovial hyperplasia and pathological neovascularisation [1,2]. Fibroblast growth factor (FGF) derived from synoviocytes may play a role in rheumatoid arthritis in stimulating their proliferation and angiogenesis [5-11]. It has been reported in an animal arthritic model that FGF over expression accelerated disease severity by increasing inflammation, swelling, angiogenesis and osteoclasstogenesis, suggesting that FGF may affect disease progression [8]. In addition, administration of an anti-FGF antibody in rats attenuated arthritic clinical symptoms and histopathological alterations [8]. Furthermore increased synovial fluid levels of FGF are associated with greater disease severity [7]. Thus, local inhibition of FGF may represent an attractive approach for the treatment of rheumatoid arthritis. Dobesilate is a powerful inhibitor of FGF that shows a markedly anti-inflammatory, anti-proliferative and anti-angiogenesis activity in several inflammation and angiogenesis-dependent diseases [12-15]. It seems obvious that all these activities may contribute to the clinical improvement of dobesilate in knee arthritic patients. Furthermore, the consequences of inhibition of FGF production by dobesilate are the direct inhibition of cell proliferation and angiogenesis. Consequently, FGF deserves further attention as a possible therapeutic target for the treatment of subject with rheumatoid arthritis.

Figure 1: Effect of etamsylate in knee rheumatoid arthritis.

Improvement of clinical manifestation of knee rheumatoid arthritis by single intraarticular injection of etamsylate in five patients. Data collected before and seven days after injection are expressed as mean SEM. Results were compared by paired t-test.*** indicates p<0.01 vs baseline.

Conclusion

In this report we present a preliminary assessment of the efficacy of the local administration of dobesilate in patients with chronic knee rheumatoid arthritis. We show that intraarticular dobesilate relieves the signs and symptoms in patients as early as one week after treatment. No relevant safety issues were observed along the study, in agreement with the good safety profile of this drug. Large scale therapeutic trials are obviously needed for more definitively establishing the efficacy of this treatment.

References

  1. Tanaka Y (2016) Current concepts in the management of rheumatoid arthritis. Korean J Intern Med 31(2): 210-218.
  2. Nakasone Y, Watabe K, Watanabe K, Tomonaga A, Nagaoka I (2011) Effect of a glucosamine-based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: A pilot study. Exp Ther Med 2(5): 893-899.
  3. Hashimoto K, Lipsky PE (1993) Immunosuppression by the disease modifying antirheumatic drug bucillamine: inhibition of human T lymphocyte function by bucillamine and its metabolites. J Rheumatol 20(6): 953-957.
  4. de Vries HS, van Oijen MG, de Jong DJ (2008) Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf 31(12): 1135-1144.
  5. Sano H, Forough R, Maier JA, Case JP, Jackson A et al. (1990) Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol 110(4): 1417-1426.
  6. Melnyk VO, Shipley GD, Sternfeld MD, Sherman L, Rosenbaum JT (1990) Synoviocytes synthesize, bind, and respond to basic fibroblast growth factor. Arthritis Rheum 33(4): 493-500.
  7. Nakashima M, Eguchi K, Aoyagi T, Yamashita I, Ida H, et al. (1994) Expression of basic fibroblast growth factor in synovial tissues from patients with rheumatoid arthritis: detection by immunohistological staining and in situ hybridisation. Ann Rheum Dis 53(1): 45-50.
  8. Yamashita A, Yonemitsu Y, Okano S, Nakagawa K, Nakashima Y (2002) Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol 168(1): 450-457.
  9. Qu Z, Huang XN, Ahmadi P, Andresevic J, Planck SR et al. (1995) Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab Invest 73(3): 339-346.
  10. Byrd V, Zhao XM, McKeehan WL, Miller GG, Thomas JW (1996) Expression and functional expansion of fibroblast growth factor receptor T cells in rheumatoid synovium and peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 39(6): 914-922.
  11. Malemud CJ (2007) Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. Clin Chim Acta 375(1-2): 10-9.
  12. Cuevas P, Angulo J, Giménez-Gallego G (2011) Topical treatment of contact dermatitis by pine processionary caterpillar. BMJ Case Rep 11: 2011.
  13. Cuevas P, Angulo J, Giménez-Gallego G (2011) Long-term effectiveness of dobesilate in the treatment of papulopustular rosacea. BMJ Case Rep 16: 2011.
  14. Fernández IS, Cuevas P, Angulo J, López-Navajas P, Canales-Mayordomo A (2010) Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J Biol Chem. 285(15): 11714-11729.
  15. Angulo J, Cuevas P, Cuevas B, El Youssef M, Fernández A (2015) Diacetyloxyl derivatization of the fibroblast growth factor inhibitor dobesilate enhances its anti-inflammatory, anti-angiogenic and anti-tumoral activities. J Transl Med 13: 48.
  16. Allain H, Ramelet AA, Polard E, Bentué-Ferrer D (2004) Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 27(9): 649-660.
© 2014-2016 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at http://medcraveonline.com
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy